| Nov 21 |
AUCATZYL's Approval Positions Autolus Therapeutics Favorably In The CAR-T Market
|
| Nov 19 |
Autolus Therapeutics upgraded to Buy from Neutral at Goldman Sachs
|
| Nov 15 |
Autolus Therapeutics Third Quarter 2024 Earnings: US$0.31 loss per share (vs US$0.26 loss in 3Q 2023)
|
| Nov 15 |
Syncona Ltd (LSE:SYNC) Half Year 2025 Earnings Call Highlights: Navigating Market Challenges ...
|
| Nov 13 |
Autolus Therapeutics PLC (AUTL) Q3 2024 Earnings Call Highlights: Strategic Advances and ...
|
| Nov 13 |
Q3 2024 Autolus Therapeutics PLC Earnings Call
|
| Nov 12 |
Autolus Therapeutics plc (AUTL) Q3 2024 Earnings Call Transcript
|
| Nov 12 |
Autolus Therapeutics plc 2024 Q3 - Results - Earnings Call Presentation
|
| Nov 12 |
Autolus Therapeutics GAAP EPS of -$0.31 misses by $0.09
|
| Nov 12 |
Autolus Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates
|
